Endoscopic Vessel Harvesting Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Endoscopic Vessel Harvesting Market Trends and Insights

Increasing Global Burden of Cardiovascular Diseases

Cardiovascular pathology affects nearly half of U.S. adults and continues to climb in many emerging economies. Growing procedure volumes make efficient conduit harvesting a strategic necessity for surgical programs managing tight bed capacity and readmission penalties. Hospitals adopting endoscopic techniques report fewer wound infections and faster ambulation, outcomes that align with modern bundled-payment incentives. The burden remains particularly high among aging cohorts with diabetes and hypertension, reinforcing the need for durable grafts and low-morbidity access sites. Governments are channeling funds into cardiac centers of excellence, catalyzing procurement of integrated EVH platforms that promise predictable learning curves and reduced staff turnover. Vendors able to document long-term graft patency and cost offsets stand to benefit most from these epidemiological tailwinds.

Growing Preference for Minimally-Invasive Harvesting

Prospective data show leg wound complications of 0.82% with endoscopic approaches versus 3% for open extraction^{[1]Maria Cannoletta et al., “Endoscopic Conduit Harvest,” Journal of Cardiothoracic Surgery, cardiothoracicsurgery.biomedcentral.com}. Patient-reported outcome measures consistently favor minimal scarring and quicker mobility, metrics now embedded in many pay-for-performance dashboards. Hospitals marketing “scar-sparing” programs gain reputational lift that translates into higher referral volumes, especially in competitive urban catchments. Widespread adoption of virtual-reality simulation has shortened operator learning curves and cut fluoroscopy exposure times by nearly one-third. Nonetheless, centers must invest in structured mentorship to avoid early complication clusters that can erode surgeon confidence. Device designers are responding with ergonomic handles and automated cutting controls to further flatten proficiency curves.

Rising Adoption of Off-Pump CABG Surgeries

Beating-heart grafting eliminates cardiopulmonary bypass-related inflammatory cascades and has shown lower mortality in patients with moderate renal dysfunction. Off-pump workflows pair naturally with endoscopic conduit harvesting because both seek to minimize physiologic insult. Robotic platforms now facilitate totally endoscopic, anaortic techniques that achieved 97.3% freedom from mitral regurgitation recurrence in a recent Japanese series^{[2]Tatsuya Tarui et al., “Totally Endoscopic Robotic Repair,” Circulation Journal, jstage.jst.go.jp}. As hybrid rooms proliferate, hospitals bundle off-pump and EVH capabilities into turnkey service lines marketed toward high-risk patients. Vendors offering interoperable robotic arms, angioscopes, and insufflation units gain a competitive edge by simplifying capital-budget decisions.

Hospitals’ Cost-Saving Shift from Open to EVH

Secondary analysis of the REGROUP trial placed discharge costs at USD 76,607 for endoscopic versus USD 75,368 for open harvest, suggesting cost neutrality at worst while generating fewer wound-related readmissions. CFOs increasingly view EVH devices as enablers of higher throughput rather than discretionary “nice-to-have” tools. Volume-based discounts on single-use kits and shared-risk contracts that rebate disposables if complication benchmarks are met are gaining favor. Meanwhile, supply-chain teams value the smaller storage footprint of sealed EVH kits compared with bulky open-harvest drapes and instruments. These operational considerations elevate purchasing criteria beyond unit price toward total-cost-of-ownership models.

Availability of Alternative Revascularization Therapies

Rapid improvements in complex percutaneous coronary intervention techniques are siphoning off some multi-vessel cases that once defaulted to coronary artery bypass grafting. Although CABG retains superiority in diabetics and diffuse disease, declining open-heart volumes in certain geographies could curb EVH unit sales. Yet, the remaining surgical cases now skew toward higher-risk profiles where minimally invasive conduit harvest offers outsized benefits. Device makers therefore position EVH as a precision tool for the subset of patients who still require grafts, emphasizing patency and wound-healing advantages versus open techniques.

Unfavorable Reimbursement in Several Countries

Health technology assessment bodies in Europe often demand long-term cost-utility data before issuing broad coverage for new disposables, delaying adoption cycles. While the July 2024 U.S. outpatient prospective payment update added new pass-through codes for select endoscopic technologies, many private insurers still require prior authorization^{[3]Centers for Medicare & Medicaid Services, “Hospital Outpatient PPS July 2024 Update,” cms.gov}. In emerging markets, capital budgets concentrate on cath labs and basic ICU beds, leaving little room for premium harvesting systems. Vendors are countering by launching low-cost towers and rental models that spread acquisition costs over procedure volume.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Systems Drive Revenue, Accessories Accelerate Growth

EVH systems generated USD 343.37 million in 2025, equal to 65.78% of the endoscopic vessel harvesting market. Hospitals purchase these capital assets once every 5-7 years, locking equipment vendors into multiyear service contracts. The accessories and disposables category, though smaller in absolute value, is growing at an 7.92% CAGR thanks to its annuity-style revenue that aligns with procedure counts. Bundled kits containing blades, scopes, and CO₂ lines simplify case setup and ensure compatibility, a convenience that purchasing managers value.

Recurring consumables are particularly attractive to ambulatory surgical centers that lack onsite sterilization capacity. Meanwhile, competitive differentiation among capital systems now hinges on image resolution, ergonomic handpieces, and analytics dashboards that log usage statistics for credentialing purposes. Getinge’s Hemopro 3 rollout exemplifies this pivot toward safety-enhanced systems designed to reassure surgeons following prior recalls.

By Vessel Type: Radial Dominance Meets Saphenous Acceleration

Radial artery conduits captured 42.12% of 2025 volume owing to superior 10-year patency, especially in younger and diabetic patients. Surgeons increasingly adopt bilateral radial strategies, boosting system utilization. Conversely, saphenous vein grafting remains indispensable when three or more distal targets must be bypassed, explaining its projected 7.48% CAGR. Evidence supporting no-touch, perivascular-preserving harvest has mitigated early skepticism regarding vein quality.

Device vendors are developing slimmer scopes and lower-pressure insufflation protocols to reduce endothelial trauma, thereby appealing to skeptics who still prefer open harvest for long conduits. Hospitals now run parallel workflows: radial for high-patency needs and optimized saphenous for multi-graft cases, a trend that increases demand for versatile system platforms.

By Usability: Disposables Lead, Reusables Resurge

Single-use kits held 64.05% of 2025 billings, reflecting infection-control priorities. However, the reusable subsegment is rebounding at 8.05% CAGR as sustainability mandates and capital-constrained public hospitals seek lifecycle savings. Manufacturers are extending reprocessing cycles through durable coatings and modular components, lowering per-case depreciation.

Environmental impact assessments, particularly in Europe, now influence tender decisions, requiring vendors to quantify waste reduction. Reusable advocates also highlight smoother instrument articulation compared with some disposable equivalents, a factor surgeons cite when performing delicate radial harvests.

By Application: CAD Dominance Amid PAD Emergence

Coronary artery disease applications accounted for 83.78% of procedures in 2025, mirroring the dominance of CABG in surgical revascularization. PAD-related harvest is smaller but expanding at 7.26% CAGR as peripheral bypasses gain favor for complex limb ischemia. Surgeons treating PAD appreciate the smaller incisions of EVH, which help fragile skin heal faster.

Reimbursement for PAD bypass varies widely, but centers adopting EVH report shorter ward stays that free capacity for lucrative structural-heart cases. Consequently, administrators view EVH as a platform technology transcending coronary indications and supporting broader vascular programs.

By End-User: Hospitals Anchor, ASCs Accelerate

General hospitals still house 58.21% of annual revenue thanks to full-service cardiac units and residency programs that ingest large patient volumes. Yet, ambulatory surgical centers will post the fastest 9.25% CAGR through 2031 as payers steer low-risk CABG candidates to lower-cost settings. EVH enables same-day ambulation and discharge pathways, making it a prerequisite for ASC accreditation in many U.S. states.

Capital-light disposable kits resonate with ASC managers who avoid large sterilizers. At the same time, hospital systems acquiring ASC chains often mandate cross-facility standardization, guaranteeing steady disposable pull-through for selected vendors.

By Harvesting Technique: CO₂ Insufflation Leads, No-Touch Gains

Closed-tunnel CO₂ insufflation methods supplied 53.02% of 2025 procedures, underpinned by two decades of clinical familiarity. The newer no-touch approach, which eschews pressurized gas to keep perivascular tissue intact, is rising at a 9.88% CAGR. Early adopters report higher long-term patency in saphenous grafts, convincing multidisciplinary boards to update protocols.

Transitioning to no-touch requires needle-free insufflators and larger working channels, prompting many sites to upgrade towers. Vendors offering conversion kits enjoy first-mover advantage, while training organizations bundle simulation modules to speed uptake.

Geography Analysis

North America generated 42.25% of 2025 turnover, underpinned by robust reimbursement and high procedural density across academic centers and community hospitals. CMS coverage consistently endorses EVH when clinically justified, and bundled-payment pilots reward shorter length of stay. Ongoing FDA engagement, including 510(k) clearances for upgraded systems, keeps innovation pipelines active. Training consortia such as STS and AATS integrate EVH modules into resident curricula, reinforcing widespread competence.

Europe follows with steady uptake driven by data-driven protocols and cross-border trials. Yet, budget caps in single-payer systems delay refresh cycles, compelling vendors to emphasize cost-utility. Scandinavian hospitals pioneered reusable scopes to satisfy environmental directives, a model now emulated in Germany and France. Mediterranean health systems, facing constrained capital budgets, gravitate toward service-leasing contracts that convert upfront equipment outlays into per-procedure fees.

Asia-Pacific is the fastest-growing territory at 9.71% CAGR through 2031, fueled by Japan’s aging population, China’s expanding middle class, and government investments in tertiary cardiac centers. Japanese surgeons have embraced totally endoscopic robotic harvests, setting performance benchmarks admired across the region. Chinese regulators increasingly fast-track cardiac devices deemed essential to public-health goals, but provincial reimbursement remains uneven. India and Southeast Asia show latent demand limited by training bottlenecks; therefore, vendors partner with medical colleges to build harvesting fellowships.

South America records moderate growth, spearheaded by Brazil’s public-private hospital network that undertakes high-volume CABG. Import taxes and currency volatility challenge foreign entrants, encouraging localized production partnerships. The Middle East and Africa present niche opportunities tied to flagship cardiac institutes in the Gulf and South Africa, yet widespread adoption is hampered by limited insurance coverage and surgeon shortages.

Market Opportunities and Future Outlook

Hospital procurement is increasingly favoring EVH platforms that reduce setup variability and support tighter process documentation, which broadens opportunities for systems that pair visualization and insufflation with disposable kits and usage logging for credentialing and quality programs. The U.S. commercial launch of Getinge's Vasoview Hemopro 3 in June 2026, following earlier FDA 510(k) clearances for Hemopro 3 variants, reinforces continued investment in workflow-oriented design, including simplified connectivity and a dedicated power supply. This direction tends to shift differentiation toward standardization, service support, and ease of use, rather than incremental scope performance alone.

Demand growth is most visible in sites expanding minimally invasive CABG pathways outside traditional tertiary centers. Ambulatory surgical centers, in particular, lean toward sealed single-use kits due to limited reprocessing capacity, while public systems and European tenders continue to create space for propositions framed around reusability and waste reduction tied to sustainability requirements. Clinical publications in 2024 and 2026 keep positioning EVH as a minimally invasive alternative to open harvesting in CABG, supporting hospital value arguments around wound-complication reduction and patient-reported recovery, and sustaining vendor interest in training-enabled adoption programs that help manage the learning curve after heightened recall scrutiny.